Effectiveness of Aspirin in Preeclampsia Prevention: Experience in Udon Thani Hospital
Keywords:
Aspirin, Preeclampsia, Prevention, Pregnancy induced hypertensionAbstract
The objective of this retrospective descriptive study was to study the effect of aspirin usage for preeclampsia prevention and the associated factors for successful outcome in Udon Thani Hospital. The medical records of the pregnancy with risk factors, who received aspirin for preeclampsia prevention during January 2016 and May 2020, were reviewed. Clinical characteristics, possible associated factors such as indication, gestational age that aspirin was started, pre-pregnancy body weight, aspirin dosage, pregnancy outcome, preeclampsia result, and complication of drug were recorded then analysed by descriptive statistic and inferential statistic used univariate and multiple logistic regression
Results: During the study period, there were 58 pregnant women who received aspirin for preeclampsia prophylaxis. The mean age was 29.5 years old (SD 6.8) and the median of gestational age that aspirin had started was 19.5 weeks. The most common indications of aspirin prevention were previous pregnancy with preeclampsia. The result of aspirin prophylaxis was 25.8% of cases developed preeclampsia with the median gestation age of delivery was 38 weeks. The mean neonatal birth weight was 3003.7 grams and the neonatal asphyxia was occurred in 3.4%. There was no serious complication from aspirin and there was no statistically significant risk factor for successful outcome.
Conclusion: There was one-fourth of the patients, who received aspirin for preeclampsia prevention, still developed preeclampsia. The gestational age that aspirin was started was late and the indications were not covered all proper indications, there fore preeclamptic risk guideline should be strictly followed for the better prevention result.
References
2. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376(9741): 631-44.
3. Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, Shackelford KA, Steiner C, Heuton KR, et al. Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014; 384(9947): 980-1004.
4. Cunningham F, Leveno K , Bloom S, Dashe J, Hoffman B, Casey B, et al. Williams Obstetrics. 25th ed. New York: Mcgraw-hill; 2018.
5. Kongwattanakul K, Saksiriwuttho P, Chaiyarach S, Thepsuthammarat K. Incidence, characteristics, maternal complications, and perinatal outcomes associated with preeclampsia with severe features and HELLP syndrome. Int J Womens Health 2018; 10: 371-7.
6. Jaikwang O SM, Anusornteerakul S, Srisaeng P. Factors affecting subtherapeutic serum magnesium levels in severe pre-eclampsia pregnant women treated with magnesium sulfate. Journal of Nursing and Health 2014; 38(2): 65-74.
7. Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H, et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet 2019; 145 Suppl 1: 1-33.
8. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol 2019; 133(1): e1-e25.
9. Visintin C, Mugglestone MA, Almerie MQ, Nherera LM, James D, Walkinshaw S, et al. Management of hypertensive disorders during pregnancy: summary of NICE guidance. BMJ 2010; 341: c2207.
10. World Health Organization. WHO recommedations for prevention and treatment of pre-eclampsia and eclampsia [Internet]. 2020 [cited 2020 July 30]. Available from: http://apps.who. int/iris/bitstream/10665/44703/1/ 978924154833 5_eng.pdf
11. Duley L, Meher S, Hunter KE, Seidler AL, Askie LM. Antiplatelet agents for preventing pre-eclampsia and its complications. The Cochrane database of systematic reviews 2019; 2019(10).
12. August P, Jeyabalan AJ. Preeclampsia: Prevention. In: UpToDate, Lockwood CJ and Barss VA (Ed), UpToDate, Waltham, MA. (Accessed on July 31, 2020.) Available from: https://www.uptodate.com/contents/pree clampsia-prevention#H20
13. Wayne W. Biostatistics: A Foundation of Analysis in the Health Sciences. 6th ed. New York: Wiley&Sons; 1995.
14. Poon LC, Wright D, Rolnik DL, Syngelaki A, Delgado JL, Tsokaki T, et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: effect of aspirin in prevention of preterm preeclampsia in subgroups of women according to their characteristics and medical and obstetrical history. AJOG 2017; 217(5): 585 e1- e5.
15. Cadavid AP. Aspirin: The Mechanism of Action Revisited in the Context of Pregnancy Complications. Frontiers in immunology 2017; 8: 261.
16. Rolnik DL, Wright D, Poon LC, O'Gorman N, Syngelaki A, de Paco Matallana C, et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. NEJM 2017; 377(7): 613-22.
17. LeFevre ML, Force USPST. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann int med 2014; 161(11): 819-26.
18. ACOG Committee Opinion No. 743: Low-Dose Aspirin Use During Pregnancy. Obstet Gynecol 2018; 132(1): e44-e52.
19. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. AJOG 1991; 165 (5 Pt 1): 1408-12.
20. Bramham K, Briley AL, Seed P, Poston L, Shennan AH, Chappell LC. Adverse maternal and perinatal outcomes in women with previous preeclampsia: a prospective study. AJOG 2011;204(6): 512 e1-9.
21. Tolcher MC, Chu DM, Hollier LM, Mastrobattista JM, Racusin DA, Ramin SM, et al. Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. AJOG 2017; 217(3): 365 e1- e8.
22. Schramm AM, Clowse ME. Aspirin for prevention of preeclampsia in lupus pregnancy. Autoimmune diseases 2014; 2014: 920467.
23. Meher S, Duley L, Hunter K, Askie L. Antiplatelet therapy before or after 16 weeks' gestation for preventing preeclampsia: an individual participant data meta-analysis. AJOG 2017; 216(2): 121-8 e2.
24. Roberge S, Nicolaides K, Demers S, Hyett J, Chaillet N, Bujold E. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. AJOG 2017; 216(2): 110-20 e6.
25. Roberge S, Bujold E, Nicolaides KH. Aspirin for the prevention of preterm and term preeclampsia: systematic review and metaanalysis. AJOG 2018; 218(3): 287-93 e1.
Downloads
Published
How to Cite
Issue
Section
License
การละเมิดลิขสิทธิ์ถือเป็นความรับผิดชอบของผู้ส่งบทความโดยตรง
ผลงานที่ได้รับการตีพิมพ์ถือเป็นลิขสิทธิ์ของผู้นิพนธ์ ขอสงวนสิทธิ์มิให้นำเนื้อหา ทัศนะ หรือข้อคิดเห็นใด ๆ ของบทความในวารสารไปเผยแพร่ทางการค้าก่อนได้รับอนุญาตจากกองบรรณาธิการ อย่างเป็นลายลักษณ์อักษร
